Nurse Guide for Novel Oral Agents in CLL: Indications and Dosing

Full abbreviations, accreditation, and disclosure information available at **PeerView.com/GKP40**

PRACTICE AID

Agent	CLL Indications	Dosing
BTKi — **Acalabrutinib[1]**	• Adult patients with CLL • In combination with obinutuzumab in patients with previously untreated CLL	100 mg PO every 12 hours taken with water; don't open, break, or chew capsules
BTKi — **Ibrutinib[2]**	• Adult patients with CLL • Adult patients with CLL and 17p deletion • Also approved for use in combination with obinutuzumab or rituximab in CLL	420 mg PO daily taken with a glass of water; don't open, break, or chew the capsules; don't cut, crush, or chew the tablets; *Note: Dosage differs from use in MCL*
BCL-2i — **Venetoclax[3]**	• Adult patients with CLL *Note: Can be used in combination with obinutuzumab or rituximab in TN-CLL and R/R CLL, respectively*	**5-week ramp up** Week 1 = 20 mg Week 2 = 50 mg Week 3 = 100 mg Week 4 = 200 mg Week 5 = 400 mg Take with a meal and water; don't chew, crush, or break tablets • **With obinutuzumab:** Initiate venetoclax on day 22 • **With rituximab:** Start rituximab after the first venetoclax cycle and 400 mg once daily for 7 days
PI3Ki — **Idelalisib[4]**	• Relapsed CLL in combination with rituximab • In patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities	150 mg PO BID
PI3Ki — **Duvelisib[5]**	• Relapsed CLL after ≥2 prior therapies	25 mg PO BID (modify dosage for toxicity)

1. Calquence (acalabrutinib) Prescribing Information. https://www.azpicentral.com/calquence/calquence.pdf#page=1. 2. Imbruvica (ibrutinib). Prescribing Information. www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing-information.pdf. 3. Venclexta (venetoclax) Prescribing Information. https://www.rxabbvie.com/pdf/venclexta.pdf. 4. Zydelig (idelalisib) Prescribing Information. https://www.gilead.com/~/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf. 5. Copiktra (duvelisib) Prescribing Information. https://copiktra.com/pdf/verastem/COPIKTRA-PI-072019.pdf.

CLL Society Resources for Nurse–to–Patient Education

Full abbreviations, accreditation, and disclosure information available at **PeerView.com/GKP40**

The mission of the CLL Society is to be an inclusive, patient-centric, physician-curated nonprofit organization that addresses the unmet needs of the CLL community through patient education, advocacy, support, and research. Here you will find highlights of helpful resources from **cllsociety.org** to better inform your practice.

CLL SOCIETY

Ask the Experts	**cllsociety.org/ask-the-expert**
CLL Support Groups	**cllsociety.org/cll-specific-patient-support-groups**
Email Alerts for CLL Breaking News	**cllsociety.org/cll_alerts**

Test Before Treat™ Resources and Handouts
cllsociety.org/cll-101/test-before-treat

Current NCCN and iwCLL guidelines indicate the importance of obtaining biomarker testing before the first treatment and again before every subsequent therapy

Test Before Treat ™
- Test FISH and TP53 Mutation before every treatment
- Test IgVH mutation status before the 1st treatment
- Deletion 17p or del(17p) = NO CHEMOTHERAPY
- TP53 mutation = NO CHEMOTHERAPY
- IgVH unmutated = NO FCR
- IgVH mutated = possible FCR

Patient Education Toolkit Binder
cllsociety.org/patient-education-toolkit

Free resource for healthcare providers and CLL/SLL patients